Akademik Veri Yönetim Sistemi
Annals of Medical Research, cilt.27, sa.3, ss.913-920, 2020 (Hakemli Dergi)
Aim: To evaluate the weight change and ghrelin, obestatin and leptin levels in operated early stage breast cancer patients receivingadjuvant chemotherapy.Material and Methods: This study was conducted with 22 operated breast cancer patients (examined before and after adjuvantchemotherapy) and 33 BMI-matched two different healthy controls (of 33 healthy controls, 17 BMI-matched control was usedto compare before adjuvant chemotherapy, 16 BMI-matched control was used to compare after adjuvant chemotherapy). Age,anthropometric measurements (weight, BMI, waist circumference), and blood biochemistry were recorded. Blood and salivary totalghrelin, obestatin and leptin levels are measured by using ELISA.Results: The mean ± SD weight (67.2 ± 12.3 and 72.9 ± 11.8 kg., p<0.001), BMI (27.3 ± 4.7 and 29.61 ± 4.4 kg/m2, p<0.001) and waistcircumference (88.6 ± 10.8 and after adjuvant chemotherapy, (93.4 ± 11.0 cm., p<0.05) values increased significantly when comparedto pre-treatment values. Acyl ghrelin (74.05 ± 50.85 and 186.47 ± 89.61 pg/ml., p<0.001 and 59.28 ± 45.74 and 151.74 ± 94.88 pg/ml., p<0.01) and des-acyl ghrelin (347.59 ± 241.95 and 936.76 ± 446.93 pg/ml., p<0.001 and 295.40 ± 241.44 and 765.38 ± 471.74pg/ml., p<0.01) serum levels were significantly lower in breast cancer patients compared to the control group in both pre-treatmentand post-treatment periods.Conclusion: In conclusion, our study confirms that adjuvant chemotherapy causes significant weight gain in early stage breastcancer patients but does not indicate a concomitant treatment related change in ghrelin, leptin or obestatin levels. The fact thatserum ghrelin levels were lower in breast cancer patients compared to BMI-matched control group, independent from treatment,might indicate that ghrelin-specific weight or adjuvant chemotherapy may be a regulatory mechanism for cancer etiopathology inbreast cancer patients.